These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 23857826)

  • 1. Health-related quality of life and symptom severity in Chinese patients with major depressive disorder.
    Cao Y; Li W; Shen J; Malison RT; Zhang Y; Luo X
    Asia Pac Psychiatry; 2013 Dec; 5(4):276-83. PubMed ID: 23857826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Association between health related quality of life and severity of depression in patients with major depressive disorder].
    Cao Y; Li W; Shen J; Zhang Y
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Feb; 36(2):143-8. PubMed ID: 21368424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients.
    Farabaugh A; Mischoulon D; Fava M; Wu SL; Mascarini A; Tossani E; Alpert JE
    Int Clin Psychopharmacol; 2005 Mar; 20(2):87-91. PubMed ID: 15729083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relief of depression and pain improves daily functioning and quality of life in patients with major depressive disorder.
    Lin CH; Yen YC; Chen MC; Chen CC
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Dec; 47():93-8. PubMed ID: 23989033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors related to the improvement in quality of life for depressed inpatients treated with fluoxetine.
    Yang WC; Lin CH; Wang FC; Lu MJ
    BMC Psychiatry; 2017 Aug; 17(1):309. PubMed ID: 28841824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of BDNF Val66Met polymorphism with both baseline HRQOL scores and improvement in HRQOL scores in Chinese major depressive patients treated with fluoxetine.
    Zou YF; Wang Y; Liu P; Feng XL; Wang BY; Zang TH; Yu X; Wei J; Liu ZC; Liu Y; Tao M; Li HC; Li KQ; Hu J; Li M; Zhang KR; Ye DQ; Xu XP
    Hum Psychopharmacol; 2010 Mar; 25(2):145-52. PubMed ID: 20196181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Negative impact of migraine on quality of life after 4 weeks of treatment in patients with major depressive disorder.
    Hung CI; Liu CY; Yang CH; Wang SJ
    Psychiatry Clin Neurosci; 2012 Feb; 66(1):8-16. PubMed ID: 22250605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Has the symptom severity inclusion requirement narrowed the definition of major depressive disorder in antidepressant efficacy trials?
    Zimmerman M; Walsh E; Chelminski I; Dalrymple K
    J Affect Disord; 2017 Mar; 211():60-64. PubMed ID: 28088058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A descriptive analysis of quality of life using patient-reported measures in major depressive disorder in a naturalistic outpatient setting.
    Ishak WW; Balayan K; Bresee C; Greenberg JM; Fakhry H; Christensen S; Rapaport MH
    Qual Life Res; 2013 Apr; 22(3):585-96. PubMed ID: 22544416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of olanzapine-fluoxetine combination treatment of major depressive disorders on the quality of life during acute treatment period.
    Qu W; Gu S; Luo H; Tang Q; Guo J
    Cell Biochem Biophys; 2014 Dec; 70(3):1799-802. PubMed ID: 25062968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and humanistic impact of potential misdiagnosis of bipolar disorder among patients with major depressive disorder in a commercially insured population.
    Kamat SA; Rajagopalan K; Pethick N; Willey V; Bullano M; Hassan M
    J Manag Care Pharm; 2008 Sep; 14(7):631-42. PubMed ID: 18774873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparable efficacy and safety of 8 weeks treatment with agomelatine 25-50mg or fluoxetine 20-40mg in Asian out-patients with major depressive disorder.
    Shu L; Sulaiman AH; Huang YS; Fones Soon Leng C; Crutel VS; Kim YS
    Asian J Psychiatr; 2014 Apr; 8():26-32. PubMed ID: 24655622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome.
    Farabaugh AH; Bitran S; Witte J; Alpert J; Chuzi S; Clain AJ; Baer L; Fava M; McGrath PJ; Dording C; Mischoulon D; Papakostas GI
    Int Clin Psychopharmacol; 2010 Jul; 25(4):214-7. PubMed ID: 20400905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of quality of life with major depressive disorder among people with HIV in South India.
    Selvaraj V; Ross MW; Unnikrishnan B; Hegde S
    AIDS Care; 2013; 25(2):169-72. PubMed ID: 22639937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pain has a strong negative impact on the fluoxetine response in hospitalized patients with major depressive disorder.
    Lin CH; Lane HY; Chen CC; Juo SH; Yen CF
    Clin J Pain; 2011; 27(9):805-10. PubMed ID: 21677571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health related quality of life in recurrent depression: a comparison with a general population sample.
    ten Doesschate MC; Koeter MW; Bockting CL; Schene AH;
    J Affect Disord; 2010 Jan; 120(1-3):126-32. PubMed ID: 19446342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship of health-related quality of life and treatment outcome during inpatient treatment of depression.
    Köhler S; Unger T; Hoffmann S; Mackert A; Ross B; Fydrich T
    Qual Life Res; 2015 Mar; 24(3):641-9. PubMed ID: 25240747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder.
    Kroenke K; Messina N; Benattia I; Graepel J; Musgnung J
    J Clin Psychiatry; 2006 Jan; 67(1):72-80. PubMed ID: 16426091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melancholic features in inpatients with major depressive disorder associate with differential clinical characteristics and treatment outcomes.
    Lin CH; Huang CJ; Liu SK
    Psychiatry Res; 2016 Apr; 238():368-373. PubMed ID: 26899817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid improvement of depression and quality of life with escitalopram treatment in outpatients with breast cancer: a 12-week, open-label prospective trial.
    Park HY; Lee BJ; Kim JH; Bae JN; Hahm BJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Mar; 36(2):318-23. PubMed ID: 22142651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.